Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

Psoriatic arthritis can have many symptoms and complications ... causes of these new symptoms and help you develop the best treatment plan. Healthline has strict sourcing guidelines and relies ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals ...

Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for ...

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, ...

SECUKINUMAB (SECU) demonstrates sustained effectiveness and high drug survival rates in patients with moderate-to-severe ...

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

Despite the availability of a variety of treatment options for psoriasis and psoriatic arthritis, both patients and health-care providers continue to seek ways to address the ongoing challenges of ...

ALEXANDRIA, VA, UNITED STATES, February 4, 2025 /EINPresswire / -- The National Psoriasis Foundation (NPF) is pleased to announce an anonymous gift o ...

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

A large European study finds that TNF inhibitors work differently across joints in psoriatic arthritis, with the shoulder and ...